國家衛生研究院 NHRI:Item 3990099045/2292

NHRI > Institute of Molecular and Genomic Medicine > Shiou-Hwei Yeh(2001-2005) > Periodical Articles > Item 3990099045/2292

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/2292

Title:	Genetic characterization of Fas-associated phosphatase-1 as a putative tumor suppressor gene on chromosome 4q21.3 in hepatocellular carcinoma
Authors:	Yeh, SH;Wu, DC;Tsai, CY;Kuo, TJ;Yu, WC;Chang, YS;Chen, CL;Chang, CF;Chen, DS;Chen, PJ
Contributors:	Division of Molecular and Genomic Medicine
Abstract:	Purpose: Allelic loss at chromosome 4q21-23 occurs frequently in human hepatocellular carcinoma, and the putative tumor suppressor gene (TSG) has not yet been identified. We studied the Fas-associated phosphatase-1 (FAP-1) gene as a potential candidate TSG in this region. Experimental Design: The expression level of FAP-1 RNA in hepatocellular carcinomas was evaluated by RNase protection and quantitative PCR. Sodium bisulfite modification and subsequent single-strand conformational polymorphism and sequence analyses were used to assay the methylation of CpGs at FAP-1 promoter. Direct sequencing of the FAP-1 coding region was conducted for detecting the genetic mutations. Two common single nucleotide polymorphisms of FAP-1 were selected for evaluating their association with the hepatocellular carcinoma trait in sporadic and familial hepatocellular carcinomas. Moreover, the functional effect of FAP-1 on cellular proliferation has been evaluated by small interfering RNA approach. Results: Around 50% of hepatocellular carcinomas showed significantly decreased expression of FAP-1 compared with the corresponding nontumorous liver tissues. In most cases, the RNA level was well correlated with the methylation status of promoter CpGs, suggesting that the promoter methylation may contribute to the down-regulation. Several genetic mutations of FAP-1 have been identified in hepatocellular carcinomas. The G/G genotype of FAP-1 cSNP6304 was significantly associated with the increased risk of multiplex familial hepatocellular carcinomas (odds ratio, 2.44; 95% confidence interval, 1.19-5.01). Finally, knockdown expression of FAP-1 was shown to enhance the cellular proliferation in PLC5 cells. Conclusions: FAP-1 could be inactivated during hepatocarcinogenesis, mainly attributed by allelic loss and promoter methylation. The genetic mutations and polymorphisms may also confront with the higher hepatocellular carcinoma risk. These results first suggested FAP-1 as a putative TSG in hepatocarcinogenesis.
Keywords:	Oncology
Date:	2006-02-15
Relation:	Clinical Cancer Research. 2006 Feb;12(4):1097-1108.
Link to:	http://dx.doi.org/10.1158/1078-0432.CCR-05-1383
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1078-0432&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000235592000005
Cited Times(Scopus):	https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84984586015
Appears in Collections:	[Shiou-Hwei Yeh(2001-2005)] Periodical Articles

Files in This Item:

File	Description	Size	Format
000235592000005.pdf		470Kb	Adobe PDF	977	View/Open

Loading...